HRT Patches Treat Prostate Cancer as Effectively as Standard Injections with Fewer Side Effects
A large UK clinical trial published in the New England Journal of Medicine demonstrates that hormone replacement therapy patches originally designed for women can treat prostate cancer as effectively as standard hormone injections while causing fewer severe side effects. The findings could fundamentally change treatment protocols for men with prostate cancer that has metastasized beyond the prostate gland. The HRT patch approach offers comparable therapeutic efficacy to current injection-based hormone treatments but with an improved safety profile, particularly regarding serious complications. This research represents a significant advancement in prostate cancer care that may improve quality of life for patients requiring long-term hormone therapy.
HRT Patches as Alternative Prostate Cancer Treatment
▪Women's HRT patches can treat prostate cancer just as effectively as standard hormone injections.
▪A large UK trial on HRT patches for prostate cancer was published in the New England Journal of Medicine.
Reduced Side Effects Compared to Standard Injections
▪Women's HRT patches used for prostate cancer treatment have fewer of the worst side effects compared to standard hormone injections.
Implications for Future Prostate Cancer Care
▪The UK trial finding on HRT patches could change how men with prostate cancer that has spread beyond the gland are treated for years to come.
Perspective of Prostate cancer patients and patient advocacy groups
▪The availability of HRT patches could reduce treatment-related complications that affect cardiovascular health in prostate cancer patients.
▪HRT patches for prostate cancer may offer patients a treatment option with better tolerability than current standard injections.
Perspective of Oncologists and medical researchers
▪The New England Journal of Medicine trial provides clinical evidence that may justify changing treatment guidelines for metastatic prostate cancer.
▪HRT patches represent a repurposing of existing hormone therapy technology for a different patient population than originally intended.
Story comments
Loading comments…